newsfilter
← Latest News
GlobeNewswire·

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug